Metallothionein expression in human breast cancer

H. Goulding, B. Jasani, H. Pereira, A. Reid, M. Galea, J. A. Bell, C. W. Elston, J. F. Robertson, R. W. Blamey, R. A. Nicholson, K. W. Schmid, I. O. Ellis

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Metallothioneins are ubiquitous low molecular weight proteins characterised by high cysteine content and affinity for binding heavy metals. Abnormal metallothionein function and expression have been implicated in various disease states, including neoplasia. The aim of this study was to investigate metallothionein expression in human breast carcinoma. Sections of routinely fixed and processed blocks of tumour from 100 consecutive cases of primary operable breast carcinoma were stained for metallothionein using a recently developed monoclonal antibody and a standard immunohistochemical technique. Expression was scored on the basis of microscopical assessment of percentage of tumour cells staining. One patient was lost to follow-up and excluded from the study. A significant association (P <0.0001) was observed between metallothionein expression and tumour type, with low levels being observed in tumours of good prognostic type. There was also a significant association with local recurrence (P <0.02) and a significant difference (P <0.02) in both survival and disease-free interval between tumours showing low and high levels of expression, the latter indicating a poor prognosis. No relationship was observed with patient age, tumour size, lymph node stage, histological grade, vascular invasion, menopausal status or oestrogen receptor status. The assessment of metallothionein expression in human breast cancer appears to provide prognostic information and may have important implications for understanding its development.

Original languageEnglish
Pages (from-to)968-972
Number of pages5
JournalBritish Journal of Cancer
Volume72
Issue number4
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Metallothionein
Breast Neoplasms
Neoplasms
Lost to Follow-Up
Heavy Metals
Estrogen Receptors
Disease-Free Survival
Cysteine
Blood Vessels
Molecular Weight
Lymph Nodes
Monoclonal Antibodies
Staining and Labeling
Recurrence
Proteins

Keywords

  • Breast carcinoma
  • Immunohistochemistry
  • Metallothionein

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Goulding, H., Jasani, B., Pereira, H., Reid, A., Galea, M., Bell, J. A., ... Ellis, I. O. (1995). Metallothionein expression in human breast cancer. British Journal of Cancer, 72(4), 968-972.

Metallothionein expression in human breast cancer. / Goulding, H.; Jasani, B.; Pereira, H.; Reid, A.; Galea, M.; Bell, J. A.; Elston, C. W.; Robertson, J. F.; Blamey, R. W.; Nicholson, R. A.; Schmid, K. W.; Ellis, I. O.

In: British Journal of Cancer, Vol. 72, No. 4, 1995, p. 968-972.

Research output: Contribution to journalArticle

Goulding, H, Jasani, B, Pereira, H, Reid, A, Galea, M, Bell, JA, Elston, CW, Robertson, JF, Blamey, RW, Nicholson, RA, Schmid, KW & Ellis, IO 1995, 'Metallothionein expression in human breast cancer', British Journal of Cancer, vol. 72, no. 4, pp. 968-972.
Goulding H, Jasani B, Pereira H, Reid A, Galea M, Bell JA et al. Metallothionein expression in human breast cancer. British Journal of Cancer. 1995;72(4):968-972.
Goulding, H. ; Jasani, B. ; Pereira, H. ; Reid, A. ; Galea, M. ; Bell, J. A. ; Elston, C. W. ; Robertson, J. F. ; Blamey, R. W. ; Nicholson, R. A. ; Schmid, K. W. ; Ellis, I. O. / Metallothionein expression in human breast cancer. In: British Journal of Cancer. 1995 ; Vol. 72, No. 4. pp. 968-972.
@article{4468e4e92a6c4e7ca5bfb3b59ae85bc6,
title = "Metallothionein expression in human breast cancer",
abstract = "Metallothioneins are ubiquitous low molecular weight proteins characterised by high cysteine content and affinity for binding heavy metals. Abnormal metallothionein function and expression have been implicated in various disease states, including neoplasia. The aim of this study was to investigate metallothionein expression in human breast carcinoma. Sections of routinely fixed and processed blocks of tumour from 100 consecutive cases of primary operable breast carcinoma were stained for metallothionein using a recently developed monoclonal antibody and a standard immunohistochemical technique. Expression was scored on the basis of microscopical assessment of percentage of tumour cells staining. One patient was lost to follow-up and excluded from the study. A significant association (P <0.0001) was observed between metallothionein expression and tumour type, with low levels being observed in tumours of good prognostic type. There was also a significant association with local recurrence (P <0.02) and a significant difference (P <0.02) in both survival and disease-free interval between tumours showing low and high levels of expression, the latter indicating a poor prognosis. No relationship was observed with patient age, tumour size, lymph node stage, histological grade, vascular invasion, menopausal status or oestrogen receptor status. The assessment of metallothionein expression in human breast cancer appears to provide prognostic information and may have important implications for understanding its development.",
keywords = "Breast carcinoma, Immunohistochemistry, Metallothionein",
author = "H. Goulding and B. Jasani and H. Pereira and A. Reid and M. Galea and Bell, {J. A.} and Elston, {C. W.} and Robertson, {J. F.} and Blamey, {R. W.} and Nicholson, {R. A.} and Schmid, {K. W.} and Ellis, {I. O.}",
year = "1995",
language = "English",
volume = "72",
pages = "968--972",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Metallothionein expression in human breast cancer

AU - Goulding, H.

AU - Jasani, B.

AU - Pereira, H.

AU - Reid, A.

AU - Galea, M.

AU - Bell, J. A.

AU - Elston, C. W.

AU - Robertson, J. F.

AU - Blamey, R. W.

AU - Nicholson, R. A.

AU - Schmid, K. W.

AU - Ellis, I. O.

PY - 1995

Y1 - 1995

N2 - Metallothioneins are ubiquitous low molecular weight proteins characterised by high cysteine content and affinity for binding heavy metals. Abnormal metallothionein function and expression have been implicated in various disease states, including neoplasia. The aim of this study was to investigate metallothionein expression in human breast carcinoma. Sections of routinely fixed and processed blocks of tumour from 100 consecutive cases of primary operable breast carcinoma were stained for metallothionein using a recently developed monoclonal antibody and a standard immunohistochemical technique. Expression was scored on the basis of microscopical assessment of percentage of tumour cells staining. One patient was lost to follow-up and excluded from the study. A significant association (P <0.0001) was observed between metallothionein expression and tumour type, with low levels being observed in tumours of good prognostic type. There was also a significant association with local recurrence (P <0.02) and a significant difference (P <0.02) in both survival and disease-free interval between tumours showing low and high levels of expression, the latter indicating a poor prognosis. No relationship was observed with patient age, tumour size, lymph node stage, histological grade, vascular invasion, menopausal status or oestrogen receptor status. The assessment of metallothionein expression in human breast cancer appears to provide prognostic information and may have important implications for understanding its development.

AB - Metallothioneins are ubiquitous low molecular weight proteins characterised by high cysteine content and affinity for binding heavy metals. Abnormal metallothionein function and expression have been implicated in various disease states, including neoplasia. The aim of this study was to investigate metallothionein expression in human breast carcinoma. Sections of routinely fixed and processed blocks of tumour from 100 consecutive cases of primary operable breast carcinoma were stained for metallothionein using a recently developed monoclonal antibody and a standard immunohistochemical technique. Expression was scored on the basis of microscopical assessment of percentage of tumour cells staining. One patient was lost to follow-up and excluded from the study. A significant association (P <0.0001) was observed between metallothionein expression and tumour type, with low levels being observed in tumours of good prognostic type. There was also a significant association with local recurrence (P <0.02) and a significant difference (P <0.02) in both survival and disease-free interval between tumours showing low and high levels of expression, the latter indicating a poor prognosis. No relationship was observed with patient age, tumour size, lymph node stage, histological grade, vascular invasion, menopausal status or oestrogen receptor status. The assessment of metallothionein expression in human breast cancer appears to provide prognostic information and may have important implications for understanding its development.

KW - Breast carcinoma

KW - Immunohistochemistry

KW - Metallothionein

UR - http://www.scopus.com/inward/record.url?scp=0028838242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028838242&partnerID=8YFLogxK

M3 - Article

VL - 72

SP - 968

EP - 972

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -